Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Tekmira and OnCore merge to create an HBV-focused company

Executive Summary

Canadian RNAi biotech Tekmira Pharmaceuticals Corp. acquired private US start-up OnCore Biopharma Inc., combining to create a hepatitis B virus (HBV) therapeutics-focused company. OnCore will become a wholly owned subsidiary of Tekmira and own 50% of the new entity, valued at $750mm.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Includes Contract
    • Intra-Biotech Deal

Related Companies